Navigation Links
NYSE Amex Provides Interleukin Genetics, Inc. Extension To Meet Continued Listing Standards
Date:3/22/2010

WALTHAM, Mass., March 22 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that the Corporate Compliance Staff of the NYSE Amex LLC (the "Exchange") has granted the Company an extension to meet the Exchange's continued listing standards and become compliant.  The Company will remain listed up to June 23, 2010, subject to periodic review by the Exchange staff during the extension period of progress towards the Company's plan to regain compliance.

As previously disclosed, Interleukin Genetics received notice from the Exchange indicating that the Company is not in compliance with Section 1003(a)(i), (ii) or (iii) of the Company Guide.

While the Company is taking steps to regain compliance with all applicable requirements for continued listing on the Exchange by June 23, 2010, there can be no assurance that the company will be able to do so in such time frame, or at all.  

About Interleukin Genetics, Inc.

Interleukin Genetics, Inc. (NYSE Amex: ILI) develops and markets genetic tests that empower consumers to prevent certain chronic diseases and that assist pharmaceutical companies in the development and marketing of targeted therapeutics. The Company leverages its research, intellectual property and biomarker development experience to facilitate the emerging personalized health market. Interleukin Genetics markets a line of genetic tests under the Inherent Health® brand including Bone Health, Weight Management, Heart Health and Nutritional Needs.  The Company is headquartered in Waltham, MA.  For more information please visit www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements, including statements regarding our ability to regain compliance with the NYSE Amex continued listing requirements by June 23, 2010.  Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Company's  annual report on Form 10-K for the year ended December 31, 2008, quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.

SOURCE Interleukin Genetics, Inc.

Back to top

RELATED LINKS
http://www.ilgenetics.com

'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
3. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
4. Raptor Pharmaceuticals Provides Update of Product Programs
5. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
6. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
7. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
10. Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
11. Improved Cornea Surgery Technique Provides Enhanced Transplant Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)...  The blood testing market in China ... Information and The Freedonia Group in a recent report.  ... The healthcare research firm said that China ... stations and in improving testing at the provincial level.  ... Blood Testing Market in China , which ...
(Date:4/28/2016)... , April 28, 2016 Dr. ... and Ste phen ... ArisGlobal®, a leading provider of cloud-based software solutions for life ... Pharmacovigilance team to bring a wealth of insight to a growing ... pharmacovigilance knowledge. George Phillips joined ArisGlobal in ...
(Date:4/28/2016)... 28, 2016  ValGenesis, Inc., the market ... (VLMS) today announced that a prominent world ... of chronic kidney failure has selected ValGenesis ... corporate validation process. The global medical device ... to manage their validation processes electronically. Upon ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... ... As directed by its board of directors during its April 26 meeting, ... certified nurse practitioners (CNP) to practice to the full scope of their license without ... years and 3,600 hours. , In addition, HAP supports CNPs who are licensed in ...
(Date:5/2/2016)... LINCOLN, R.I. (PRWEB) , ... May 02, 2016 ... ... , an educational website to help consumers better understand life insurance throughout various ... helpful resources, including an easy-to-use life insurance needs calculator and content specific to ...
(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Philip Shindler, ... with same day treatments. In the past, many necessary dental treatments could require multiple ... with multiple anesthetic shots and extra chair time. Not only could this be inconvenient, ...
(Date:5/2/2016)... ... 2016 , ... Further establishing itself as a leader in natural pet products ... Boxes were selected from over 1,000 entrants as a winner and recipient of the ... chews for dogs are a favorite product among pet-parents worldwide, as each whimsical knobby ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... that many commonly used prescription medications, including anxiolytics, painkillers, antidepressants and cholesterol-lowering ... risks, Novus Medical Detox Center —a leading Florida-based drug treatment facility—advises ...
Breaking Medicine News(10 mins):